搜索结果
靶点ID:TCMBANKGE010862
靶点别名:ACHRD; CMS2A; CMS3A; CMS3B; CMS3C; FCCMS; SCCMS
靶点描述:cholinergic receptor nicotinic delta subunit
染色体:2
染色体位置:2q37.1
靶点类型:protein-coding
HERB_ID:-
HGNC_Link:1965
OMIM_Link:100720
Ensembl_Link:ENSG00000135902
靶点对应的植物
| ID | 拉丁名 | 药名 | 药用植物名 | 功能与主治 | 来源 | 药用部位 | 使用民族 |
|---|
靶点对应的化合物
| 化合物ID | 化合物名 | 别名 | 分子式 | 分子质量 | Smiles |
|---|
| TCMBANKIN008636 | acetylcholine | Vagusstoff; AC1NSTAT; Acetylcholine Hydroxide; 2-acetyloxyethyl(trimethyl)azanium hydroxide; SCHEMBL3904052; 56-13-3 | C7H16NO2+ | 146.21 g/mol | CC(=O)OCC[N+](C)(C)C |
| TCMBANKIN009686 | a-bungarotoxin | C50H70O14 | CC1CC2C(CC3(C(O2)CC4C(O3)C(=CC(=O)O4)C)C)OC5C1OC6CC7C(CC8C(O7)(CC=CC9C(O8)CC1C(O9)CC2C(O1)(C(CC(O2)CC(=C)C=O)O)C)C)(OC6(CC5)C)C | ||
| TCMBANKIN018400 | 1ycorenium A | C18H38I2N2O4 | C[N+](C)(C)CCOC(=O)CCCCCCC(=O)OCC[N+](C)(C)C.[I-].[I-] | ||
| TCMBANKIN057992 | betaine | Betaine; Aristolochic acid; EINECS 258-258-7; Betaine aspartate; carboxy-n,n,n-trimethylmethanaminium(3s)-3-amino-3-carboxypropanoate; TRIMETHYL GLYCINE (+)-ASPARTATE; AC1L2WMU; D07524; betaine hydrochloride; Somathl (TN); glycine betaine; (2S)-2-amino-4-hydroxy-4-oxobutanoate; carboxymethyl(trimethyl)azanium; aristolochic acid A; AC1Q5T26 | C5H11NO2 | 117.15 g/mol | C[N+](C)(C)CC(=O)[O-] |
| TCMBANKIN058425 | serotonine | AC1L1JTO; Oprea1_712368; KBio2_007608; Tryptamine, 5-hydroxy-; NCGC00142449-02; Ds substance; 6996AB; NCGC00015525-08; Bio2_000396; 14C-5-hydroxy tryptamine creatinine disulfate; KBioGR_002472; 6F7FD5B4-A558-45F0-A20A-2D068A3EFE6A; NCGC00015525-06; NCGC00142449-03; CHEMBL39; Prestwick1_000481; NCGC00015525-02; KBio3_000843; CH-132; ALBB-006183; FT-0631212; MolPort-001-779-633; BRN 0143524; 3-(.beta.-Aminoethyl)-5-hydroxyindole; PDSP1_001512; 1H-Indol-5-ol, 3-(2-aminoethyl)-; KBio2_005040; AX8011985; KBioGR_000452; 5-Hydroxytryptamine, free base; DTXSID8075330; NCGC00142449-04; KBio3_002950; Indol-5-ol, 3-(2-aminoethyl)-; Substanz DS; Antemovis; KBio2_000452; L000078; IDI1_002151; Prestwick0_000481; 5-Hydroxy-3-(beta-aminoethyl)indole; AC1Q54C0; serotonin; Prestwick2_000481; LS-83647; 5-Hydroxytryptamine, 5-HT, Enteramine; KBio2_002472; Hippophain; 5-hydroxy-tryptamine; KBio2_005588; Substance DS; SPBio_002262; 2-imino-1-methylimidazolidin-4-one; 3-(2-aminoethyl)-1H-indol-5-ol; bis(sulfuric acid); Biomol-NT_000083; BDBM10755; HMS3403H13; AKOS001484724; NCGC00015525-05; C-06146; HMS1362H13; 5-Hydroxytriptamine; API0006544; I14-1899; ZINC57058; HMS1990H13; Bio2_000876; KB-177045; A-Aminoethyl)-5-hydroxyindole, Thrombotonin; Thrombocytin; CC-21879; NCGC00015525-09; NCGC00142449-05; 3-(2-Aminoethyl)-1H-indol-5-ol #; Enteramine; KBioSS_002479; HMS1792H13; 5-Hydroxy-3-(.beta.-aminoethyl)indole; CAS-153-98-0; 5-Hta; STK503758; GTPL5; KBio3_000844; CTK4J2994; 5-22-12-00016 (Beilstein Handbook Reference); Thrombotonin; 5-hydroxyl tryptamine; AJ-09556; Serotonine; Thrombocytin, 3-(; Bio1_001428; BCBcMAP01_000198; cMAP_000059; EINECS 200-058-9; 5-Hydroxyltryptamine; K-9367; Hippophaine; 3-(beta-Aminoethyl)-5-hydroxyindole; DB-051820; 50-67-9; C00780; BPBio1_001079; Prestwick3_000481; BSPBio_001112; 5-Hydroxy-3-(b-aminoethyl)indole; 333DO1RDJY; SMP1_000272; MCULE-8788459983; Lopac0_000607; H-8000; AK115646; D0F6CD; NCGC00015525-07; 3-(b-Aminoethyl)-5-hydroxyindole; Lopac-H-9523; Bio1_000450; Antemoqua; 5-HYDROXYTRYPTAMINE; BPBio1_000377; TR-018115; Serotonin, analytical standard; KBio2_003020; 3-(2-Aminoethyl)indol-5-ol; STOCK1N-48365; KBioSS_000452; NCGC00142449-01; 3-(2-Aminoethyl)-1H-indol-5-ol; NCGC00015525-04; 1H-Indol-5-ol,3-(2-aminoethyl)-; 5-hydroxy tryptamine creatinine disulfate; 3-(2-Amino-ethyl)-1H-indol-5-ol; NCGC00015525-03; Enteramin; CCG-204696; bmse000757; QZAYGJVTTNCVMB-UHFFFAOYSA-N; CHEBI:28790; UNII-333DO1RDJY; BSPBio_000341; AN-41571; SCHEMBL1495; BG01504460; PDSP2_001496; Bio1_000939; 5-HT; NCGC00015525-01; FCH832159; BG00601775;Serotonin;AIDS-166243; Indol-5-ol, 3-(2-aminoethyl)-; 5-Hydroxytryptamine; Oprea1_712368; KBio2_007608; Substanz DS; Antemovis; Lopac-H-9523; Thrombocytin; Bio1_000450; Antemoqua; KBio2_000452; Tryptamine, 5-hydroxy-; IDI1_002151; Prestwick0_000481; BPBio1_000377; 5-Hydroxy-3-(beta-aminoethyl)indole; Ds substance; Enteramine; AIDS166243; KBio2_003020; KBioSS_002479; 3-(2-Aminoethyl)indol-5-ol; serotonin; Prestwick2_000481; Bio2_000396; NCGC00142449-01; KBioGR_002472; KBioSS_000452; 3-(2-Aminoethyl)-1H-indol-5-ol; 5-Hta; CAS-153-98-0; KBio2_002472; KBio3_000844; 5-22-12-00016 (Beilstein Handbook Reference); Hippophain; Thrombotonin; NCGC00142449-03; Serotonine; KBio2_005588; Substance DS; Prestwick1_000481; SPBio_002262; NCGC00015525-02; Biomol-NT_000083; KBio3_000843; CHEBI:28790; BSPBio_000341; Bio1_001428; cMAP_000059; BCBcMAP01_000198; EINECS 200-058-9; BB_NC-1185; BRN 0143524; PDSP1_001512; 3-(beta-Aminoethyl)-5-hydroxyindole; PDSP2_001496; 50-67-9; 1H-Indol-5-ol, 3-(2-aminoethyl)-; KBio2_005040; C00780; BPBio1_001079; Bio1_000939; Prestwick3_000481; NCGC00015525-01; KBioGR_000452; Bio2_000876; BSPBio_001112; SMP1_000272; Lopac0_000607; NCGC00142449-04; KBio3_002950 | C10H12N2O | 176.21 g/mol | C1=CC2=C(C=C1O)C(=CN2)CCN |
| TCMBANKIN058627 | (+-)-anabasine | C10H14N2 | 162.23 g/mol | C1CCNC(C1)C2=CN=CC=C2 | |
| TCMBANKIN058858 | ginsenoside- Rg1 | ginsenoside-rg1;(2R,3R,4S,5S,6R)-2-[[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-17-[(1S)-1,5-dimethyl-1-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2-tetrahydropyranyl]oxy]hex-4-enyl]-3,12-dihydroxy-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H; (2R,3R,4S,5S,6R)-2-[[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2S)-6-methyl-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a; (2R,3R,4S,5S,6R)-2-[[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-17-[(1S)-1,5-dimethyl-1-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-methylol-tetrahydropyran-2-yl]oxy-hex-4-enyl]-3,12-dihydroxy-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclop; (2R,3R,4S,5S,6R)-2-[[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2S)-6-methyl-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[; C08946; (2R,3R,4S,5S,6R)-2-[[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-17-[(1S)-1,5-dimethyl-1-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-hex-4-enyl]-3,12-dihydroxy-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-; 22427-39-0; sanchinoside rg1; Sanchinoside C1 | C42H72O14 | 801.01 g/mol | CC(=CCCC(C)(C1CCC2(C1C(CC3C2(CC(C4C3(CCC(C4(C)C)O)C)OC5C(C(C(C(O5)CO)O)O)O)C)O)C)OC6C(C(C(C(O6)CO)O)O)O)C |
靶点对应的疾病
| 疾病ID | 疾病名 | MeSH名 | HPO名 | UMLS名 | 疾病类型 |
|---|
| TCMBANKDI000576 | - | Abnormality of the nervous system | Anatomical Abnormality | disease | |
| TCMBANKDI001147 | - | - | Disease or Syndrome | disease | |
| TCMBANKDI002456 | - | Abnormality of limbs; Abnormality of the skeletal system | Finding | phenotype | |
| TCMBANKDI002606 | Pathological Conditions, Signs and Symptoms; Respiratory Tract Diseases | Abnormality of the respiratory system | Sign or Symptom | phenotype | |
| TCMBANKDI003215 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases | Abnormality of the nervous system | Disease or Syndrome | disease | |
| TCMBANKDI003685 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases | Abnormality of prenatal development or birth | Disease or Syndrome | disease | |
| TCMBANKDI004134 | - | Abnormality of the respiratory system | Finding | phenotype | |
| TCMBANKDI004489 | - | Abnormality of the ear | Congenital Abnormality | disease | |
| TCMBANKDI005627 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Cardiovascular Diseases | Abnormality of the cardiovascular system | Finding | phenotype | |
| TCMBANKDI006903 | - | Abnormality of limbs; Abnormality of the musculature | phenotype | ||
| TCMBANKDI007525 | Pathological Conditions, Signs and Symptoms; Musculoskeletal Diseases; Nervous System Diseases | Abnormality of the musculature | Finding | phenotype | |
| TCMBANKDI007707 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nervous System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI009106 | Pathological Conditions, Signs and Symptoms; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Skin and Connective Tissue Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI011779 | - | Abnormality of the skeletal system | Anatomical Abnormality | disease | |
| TCMBANKDI012363 | - | Abnormality of the musculature | Finding | phenotype | |
| TCMBANKDI013927 | Respiratory Tract Diseases | Abnormality of the respiratory system | Pathologic Function | phenotype | |
| TCMBANKDI018929 | Eye Diseases | Abnormality of the eye | Disease or Syndrome | disease | |
| TCMBANKDI018939 | Pathological Conditions, Signs and Symptoms; Musculoskeletal Diseases; Nervous System Diseases | Abnormality of the musculature | Finding | phenotype | |
| TCMBANKDI020373 | - | Abnormality of the musculature | Pathologic Function | phenotype | |
| TCMBANKDI020574 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases; Stomatognathic Diseases | Abnormality of the nervous system; Abnormality of head or neck; Abnormality of the musculature | Disease or Syndrome | disease | |
| TCMBANKDI021038 | - | Abnormality of the skeletal system | Finding | phenotype | |
| TCMBANKDI021821 | Neoplasms; Immune System Diseases; Nervous System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI022380 | Female Urogenital Diseases and Pregnancy Complications | Abnormality of prenatal development or birth | Pathologic Function | phenotype | |
| TCMBANKDI024559 | - | Abnormality of head or neck | Finding | phenotype | |
| TCMBANKDI025894 | - | Abnormality of head or neck; Abnormality of the musculature | Anatomical Abnormality | phenotype | |
| TCMBANKDI026317 | - | - | Disease or Syndrome | disease | |
| TCMBANKDI027406 | - | Abnormality of the nervous system; Abnormality of the musculature | Finding | phenotype | |
| TCMBANKDI030716 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases | Abnormality of the nervous system | Finding | phenotype | |
| TCMBANKDI031438 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases | Abnormality of the nervous system | Finding | phenotype | |
| TCMBANKDI032109 | Pathological Conditions, Signs and Symptoms | - | Disease or Syndrome | disease |
滇IICP备16009434号-1 |
Dai SX Lab